MEN 1309

Drug Profile

MEN 1309

Alternative Names: MEN-1309; OBT 076

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioTherapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action DEC-205 receptor modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Bladder cancer; Breast cancer; Non-Hodgkin's lymphoma; Pancreatic cancer

Most Recent Events

  • 12 Sep 2017 Phase-I clinical trials in Solid tumours in Belgium (unspecified route)
  • 12 Sep 2017 Phase-I clinical trials in Solid tumours in Italy (unspecified route)
  • 12 Sep 2017 Phase-I clinical trials in Solid tumours in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top